Vericel (VCEL) Change in Accured Expenses (2010 - 2026)
Vericel (VCEL) posted Change in Accured Expenses of $3.7 million for Q2 2026, up 169.86% sequentially from -$5.3 million in Q1 2026, and up 21.77% YoY from $3.0 million in Q2 2025.
Analysis
Vericel (VCEL) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Vericel has reported Change in Accured Expenses for 17 years, with the latest figure at $3.7 million in Q2 2026.
- Quarterly Change in Accured Expenses rose 21.77% year-over-year to $3.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.3 million (up 72.68% YoY) and the FY2025 annual result came in at $2.2 million, up 959.02% from the prior year.
- Change in Accured Expenses improved to $3.7 million in Q2 2026 per VCEL's latest filing, from -$5.3 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $3.7 million in Q2 2026 and troughed at -$6.2 million in Q1 2024.
- A 5-year average of $219888.9 and a median of $1.7 million in 2024 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 1351.72% in 2022, down 181.17% in 2022.
- Over 5 years, Change in Accured Expenses stood at $2.2 million in 2022, then soared by 59.99% to $3.6 million in 2023, then slipped by 13.8% to $3.1 million in 2024, then sank by 56.4% to $1.3 million in 2025, then jumped by 173.07% to $3.7 million in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $3.7 million, -$5.3 million, and $1.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 3.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.68 Mn |
| Mar 31, 2026 | -5.27 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Sep 30, 2025 | 3.52 Mn |
| Jun 30, 2025 | 3.02 Mn |
| Mar 31, 2025 | -5.72 Mn |
| Dec 31, 2024 | 3.09 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Mar 31, 2024 | -6.20 Mn |
| Dec 31, 2023 | 3.59 Mn |
| Sep 30, 2023 | -343,000.00 |
| Jun 30, 2023 | 860,000.00 |
| Mar 31, 2023 | -3.08 Mn |
| Dec 31, 2022 | 2.24 Mn |
| Sep 30, 2022 | 1.82 Mn |
| Jun 30, 2022 | 1.82 Mn |
| Mar 31, 2022 | -3.73 Mn |
| Dec 31, 2021 | 3.11 Mn |
| Sep 30, 2021 | -145,000.00 |